Success Stories: NAILG Helps Molecular Biology Scientist Secure NIW for Transformative Cancer Research
Client’s Testimonial:
“Thank you for your support of me getting I-140 approval.”
On February 28th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Research Scientist in the Field of Molecular Biology (Approval Notice).
General Field: Molecular Biology
Position at the Time of Case Filing: Research Scientist
Country of Origin: Iran
State of Residence at the Time of Filing: Maryland
Approval Notice Date: February 28th, 2025
Processing Time: 1 year, 3 months, 15 days
Case Summary:
North America Immigration Law Group (NAILG) successfully secured EB-2 NIW approval for a distinguished molecular biologist whose work is shaping the future of cancer treatment. Her research focuses on uncovering the roles of specific proteins and signaling pathways in cancer development and progression, with the goal of designing highly effective, targeted therapies that address urgent medical needs and improve patient survival rates.
She advances this mission both by studying compounds that disrupt essential survival signals in cancer cells and by deepening the scientific understanding of how cancers initiate and progress. This dual approach directly supports ongoing efforts to enhance the precision and effectiveness of cancer therapies in the United States and worldwide.
Her professional record demonstrates her deep expertise and influence in the field:
- Completion of at least 3 peer reviews for respected scientific journals
- Authorship of 26 peer-reviewed journal articles, including 10 as first author
- A total of 546 citations to her published work
- Receipt of research funding from the Canadian Institutes of Health Research (CIHR)
"[Client] is working in an area of great national and international importance, as developments in molecular biology directly impact the biopharmaceutical industry. Considering the merit of her research in conjunction with her publication in selective journals and the recognition of her work across the field, [Client] has clearly established herself as a valued leader and frontier scientist in the field of molecular biology."
With NIW approval now secured, she is poised to expand her pioneering work in the United States, furthering the development of targeted cancer therapies and making lasting contributions to public health and medical science. NAILG is honored to have played a role in helping her achieve this important milestone.

